Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 210

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Effects of the Long-Term Administration of Nebivolol on the Clinical Symptoms, Exercise Capacity, and Left Ventricular Function of Patients with Diastolic Dysfunction: Results of the ELANDD Study

Open access
Conraads, Viviane M., Metra, Marco, Kamp, Otto, De Keulenaer, Gilles W., Pieske, Burkert, Zamorano, José, Vardas, Panos E., Böhm, Michael, Dei Cas, Livio·2012·European Journal of Heart Failure

Abstract

Aims: We hypothesized that nebivolol, a beta-blocker with nitric oxide-releasing properties, could favourably affect exercise capacity in patients with heart failure and preserved left ventricular ejection fraction (HFPEF). Methods and results: A total of 116 subjects with HFPEF, in New York Heart Association (NYHA) functional class II–III, with left ventricular ejection fraction (LVEF) >45%, and with echo-Doppler signs of LV diastolic dysfunction, were randomized to 6 months treatment with nebivolol or placebo, following a double-blind, parallel group design. The primary endpoint of the study was the change in 6 min walk test distance (6MWTD) after 6 months. Nebivolol did not improve 6MWTD (from 420 ±143 to 428 ±141 m with nebivolol vs. from 412 ±123 to 446 ±119 m with placebo, P = 0.004 for interaction) compared with placebo, and the peak oxygen uptake also remained unchanged (peakVO2; from 17.02 ±4.79 to 16.32 ±3.76 mL/kg/min with nebivolol vs. from 17.79 ±5.96 to 18.59 ±5.64 mL/kg/min with placebo, P = 0.63 for interaction). Resting and peak blood pressure and heart rate decreased with nebivolol. A significant correlation was found between the change in peak exercise heart rate and that in peakVO2 (r = 0.391; P = 0.003) for the nebivolol group. Quality of life, assessed using the Minnesota Living with Heart Failure™ Questionnaire, and NYHA classification improved to a similar extent in both groups, whereas N-terminal pro brain natriuretic peptide (NT-pro BNP) plasma levels remained unchanged. Conclusions: Compared with placebo, 6 months treatment with nebivolol did not improve exercise capacity in patients with HFPEF. Its negative chronotropic effect may have contributed to this result.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurjhf/hfr161

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 210

Metadata

Authors
Conraads, V. M., Metra, M., Kamp, O., De Keulenaer, G. W., Pieske, B., Zamorano, J., Vardas, P. E., Böhm, M., & Dei Cas, L.
Venue
European Journal of Heart Failure
Published
2012-02-01
Volume
14
Issue
2
Pages
219-225
ISSN
  • 1388-9842 (ISSN-L)
  • 1879-0844
OpenAlex
W2161444540
Cited by
210
References
2
FWCI
8.41
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of the Long-Term Administration of Nebivolol on the Clinical Symptoms, Exercise Capacity, and Left Ventricular Function of Patients with Diastolic Dysfunction: Results of the ELANDD Study. https://app.cochat.ai/papers/10.1093/eurjhf/hfr161
The paper
Conraads, V. M., Metra, M., Kamp, O., De Keulenaer, G. W., Pieske, B., Zamorano, J., Vardas, P. E., Böhm, M., & Dei Cas, L. (2012). Effects of the Long-Term Administration of Nebivolol on the Clinical Symptoms, Exercise Capacity, and Left Ventricular Function of Patients with Diastolic Dysfunction: Results of the ELANDD Study. European Journal of Heart Failure. https://doi.org/10.1093/eurjhf/hfr161

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.